We want to boost your innovative project or start-up by lowering the entry barriers for life science entrepreneurs and creating entrepreneurial opportunities, so together, we can fuel the next generation of innovators and life-saving technologies.
Based in Denmark, our company started small as well, and today we are more than 65,000 people, across the globe, discovering, developing, and co-creating solutions to healthcare challenges for people living with diabetes, obesity, cardiovascular disease, MASH, chronic kidney disease, and blood and endocrine disorders. Treatments and patient care have come a long way, and together, we can continue driving change to improve the lives of patients.
That’s why we hope you will join us in our call for applications below.
We are partnering with the premiere life-sciences incubator, BioLabs, so you can join their network through the Science2Medecine creatioNN programme that offers rent-free lab spaces at two of their European hubs, either at BioLabs Heidelberg, located in Germany, or at BioLabs Paris, located in the heart of the city, in the hospital setting of Hôtel-Dieu.
It is more than just a lab space: it is an entrepreneurial base for your laboratory work and entry to the ecosystem network of other biotech start-up firms alike. At each life science incubator, you will not only get access to a dedicated lab bench, but also to shared facilities so you can concentrate on your innovative science, while BioLabs takes care of the lab management. Each ticket provides 1 bench, 1 desk and a membership for 1 year.
In addition, the program will enable you to work closely with Novo Nordisk scientific R&D experts and offer a gateway for further collaboration.
Are you interested to reside among the biotech and superstars, working on developing breakthrough innovations in the cardiometabolic space? Scroll down and send us your application and unique value proposition that addresses a significant unmet need for patients with cardio-metabolic diseases.
Application deadline is on the 20th January 2025 by 12:00 pm Central European Time.
- Efficacy beyond blood glucose lowering, e.g. co-morbidity risk reduction
- Reversal of insulin resistance
- Prevention
of disease progression, e.g. preservation of beta-cell health
(T1D/T2D)
- Enhancing energy expenditure
- Modulating hedonic eating behavior (e.g. hedonic
- and reward signalling)
- Modulation of the counter-regulatory mechanisms (e.g. metabolic
set-point)
- Atherosclerotic CVD, HFpEF & cardiomyopathies
- MoAs providing risk reduction additive to LDL/TG lowering and anti-inflammation
- Precision-medicine approaches to heart failure
- Disease-modification (e.g. gene therapy)
- CKD/DKD, polycystic, kidney disease & glomerulonephritis
- Fibrosis resolution/inhibition of fibrogenesis
- Preservation of vascular and glomerular
integrity
- Fibrosis resolution/inhibition of fibrogenesis
- Suppression of chronic inflammation
- Liver regenerative approaches
- Non-invasive diagnostic biomarkers
- Rare, non-malignant hematologic diseases
- Rare
endocrine diseases
in the above stated therapeutic areas
Submit applications
by January 20, 2025
A subset of applicants will be identified as finalists by the contest judges by the end on February, 2025
Finalists will present their company & scientific concept at a live event on March 11, 2025
Four awards will be granted. Good luck!
